We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

166 hedge funds and large institutions have $444M invested in Verve Therapeutics in 2024 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 63 increasing their positions, 54 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more capital invested

Capital invested by funds: $365M → $444M (+$79.3M)

17% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 54

3.96% more ownership

Funds ownership: 88.95% → 92.92% (+4%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less funds holding

Funds holding: 174 → 166 (-8)

21% less call options, than puts

Call options by funds: $734K | Put options by funds: $926K

23% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 26

Holders
166
Holders Change
-8
Holders Change %
-4.6%
% of All Funds
2.19%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
20
Increased
63
Reduced
54
Closed
26
Calls
$734K
Puts
$926K
Net Calls
-$192K
Net Calls Change
+$579K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$35.3M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$7.86M
3
SSA
Schonfeld Strategic Advisors
New York
+$7.8M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$1.63M
5
BlackRock
BlackRock
New York
+$1.41M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$6.94M
2
Millennium Management
Millennium Management
New York
-$5.89M
3
State Street
State Street
Massachusetts
-$5.74M
4
Citadel Advisors
Citadel Advisors
Florida
-$3.47M
5
CSS
Cubist Systematic Strategies
Connecticut
-$3.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$3.22M -$8.21K -1,455 -0.3%
Two Sigma Investments
27
Two Sigma Investments
New York
$3.22M +$790K +140,030 +33%
Bank of America
28
Bank of America
North Carolina
$3.09M -$1.29M -228,551 -29%
Dimensional Fund Advisors
29
Dimensional Fund Advisors
Texas
$2.46M +$30K +5,320 +1%
JP Morgan Chase
30
JP Morgan Chase
New York
$2.35M -$6.94M -1,230,305 -75%
Renaissance Technologies
31
Renaissance Technologies
New York
$2.05M -$1.19M -211,386 -37%
Wellington Management Group
32
Wellington Management Group
Massachusetts
$2.04M +$81.6K +14,469 +4%
CAM
33
Cormorant Asset Management
Massachusetts
$1.97M – – –
Two Sigma Advisers
34
Two Sigma Advisers
New York
$1.65M +$613K +108,600 +59%
SFI
35
Susquehanna Fundamental Investments
Pennsylvania
$1.64M +$1.64M +291,383 New
Ameriprise
36
Ameriprise
Minnesota
$1.46M +$185K +32,817 +15%
Los Angeles Capital Management
37
Los Angeles Capital Management
California
$1.3M -$176K -31,270 -12%
Barclays
38
Barclays
United Kingdom
$1.24M -$12.3K -2,188 -1%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$1.24M +$29.7K +5,262 +2%
AG
40
Algert Global
California
$1.06M -$204K -36,211 -16%
IC
41
Ikarian Capital
Texas
$959K -$51 -9 -0%
ACP
42
Acuta Capital Partners
California
$904K +$79.5K +14,100 +10%
Jane Street
43
Jane Street
New York
$881K -$342K -60,673 -28%
JF
44
Jump Financial
Illinois
$834K +$173K +30,661 +26%
Mirae Asset Global ETFs Holdings
45
Mirae Asset Global ETFs Holdings
Hong Kong
$816K +$116K +20,483 +16%
Stifel Financial
46
Stifel Financial
Missouri
$796K +$54.9K +9,736 +7%
UBS Group
47
UBS Group
Switzerland
$788K -$137K -24,338 -15%
GCP
48
GSA Capital Partners
United Kingdom
$785K +$581K +103,057 +285%
Rafferty Asset Management
49
Rafferty Asset Management
New York
$769K -$420K -74,539 -35%
Swiss National Bank
50
Swiss National Bank
Switzerland
$751K +$102K +18,000 +16%
1
2
3 4 5

VERV Hedge Fund Activity: Q4 2024 in Review

166 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q4 2024, worth a combined $444M — up 22% from $365M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of VERV and 20 opened new positions — a net loss of 6 holders — while 54 trimmed existing stakes and 63 added.

The largest buyer was BVF Inc, adding an estimated $35.3M. The largest seller was JP Morgan Chase, cutting an estimated $6.94M.

  • 166 institutional investors held Verve Therapeutics (VERV) as of Q4 2024, down from 174 in Q3 2024.
  • Funds reported $444M of Verve Therapeutics stock for Q4 2024, up 22% quarter-over-quarter.
  • 20 funds opened new Verve Therapeutics positions in Q4 2024 and 26 closed out, a net change of -6 holders.
  • The largest Verve Therapeutics buyer in Q4 2024 was BVF Inc, an estimated $35.3M added.
  • The largest Verve Therapeutics seller in Q4 2024 was JP Morgan Chase, an estimated $6.94M sold.

Based on aggregated 13F filings for Q4 2024.